Kaufman, J.M., Devogelaer, J.P., Raeman, F., Prevention and treatment of postmenopausal osteoporosis: National consensus of the Belgian bone club (1997) Clin Rheum, 16, pp. 343-345
Black, D.M., Cummings, S.R., Karpf, D.B., Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures (1996) Lancet, 348, pp. 1535-1541
Jensen, G.F., Christiansen, C., Transbol, I., Fracture frequency and bone preservation in postmenopausal women treated with estrogen (1982) Obstet Gynecol, 60, pp. 493-496
Liberman, U., Weiss, S.R., Broll, J., Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis (1995) N Engl J Med, 333, pp. 1437-1443
Overgaard, K., Hansen, M.A., Jensen, S.B., Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study (1992) BMJ, 305, pp. 556-561
Watts, N.B., Harris, S.T., Genant, H.K., Intermittent cyclical etidronate treatment of postmenopausal osteoporosis (1990) N Engl J Med, 323, pp. 73-79
Reginster, J.Y., Oral tiludronate: Pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis (1992) Bone, 13, pp. 351-354
Zegels, B., Balena, R., Eastell, R., Effect of risedronate on collagen cross links in postmenopausal osteoporosis (1995) J Bone Miner Res, 10 (SUPPL. 1), p. 455
Riggs, B.L., Melton, L.J., Involutional osteoporosis (1986) N Engl J Med, 914, pp. 1676-1684
Dempster, D.W., Cosman, F., Parisien, M., Anabolic actions of parathyroid hormone on bone (1993) Endocr Rev, 14, pp. 690-709
Pugsley, L.I., Selye, H., The histological changes in the bone responsible for the action of parathyroid hormone on the calcium metabolism of the rat (1993) J Physiol (Lond), 79, pp. 113-117
Podbesek, R., Edouard, C., Meunier, P.J., Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds (1983) Endocrinology, 112, pp. 1000-1005
Canalis, E., McCarthy, T.L., Centrella, M., Differential effects of continuous and transient treatment with parathyroid hormone related peptide (PTHrp) on bone collagen synthesis (1990) Endocrinology, 126, pp. 1806-1812
Reeve, J., PTH: A future role in the management of osteoporosis? (1996) J Bone Miner Res, 11, pp. 440-445
Mosekilde, L., Sogaard, C.H., McOsker, J.E., Wronski, T.J., PTH has a more pronounced effect on vertebral bone mass and biochemical competence than antiresorptive agents (estrogen and bisphosphonate) assessed in sexually mature, ovariectomized rats (1994) Bone, 15, pp. 401-408
Sogaard, C.H., Wronski, T.J., McOsker, J.E., The positive effect of parathyroid hormone on femoral neck bone strength in ovariectomized rats is more pronounced than that of estrogen or bisphosphonates (1994) Endocrinology, pp. 134-650
Ejersted, C., Andreassen, T.T., Nilsson, M.H.L., Human parathyroid hormone (1-34) increases bone formation and strength of cortical bone in aged rats (1994) Eur J Endocrinol, 130, pp. 201-207
Eriksen, E.F., Melsen, F., Mosekilde, L., Drug therapy: Formation-stimulating regimens (1995) Osteoporosis: Etiology, Diagnosis and Management, pp. 403-434. , Philadelphia: Lippincott-Raven
Reeve, J., Arlot, M.E., Price, T.R., Periodic courses of human 1-34 parathyroid peptide alternating with calcitriol paradoxically reduce bone remodeling in spinal osteoporosis (1987) Eur J Clin Invest, 17, pp. 421-428
Slovick, D.M., Neer, R.M., Potts, J.T., Short-term effects of synthetic-human parathyroid hormone (1-34) administration on bone mineral metabolism in osteoporotic patients (1981) J Clin Invest, 68, pp. 1261-1271
Finkeistein, J.S., Klibanski, A., Schaefer, E.H., Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency (1994) N Engl J Med, 331, pp. 1618-1623
Hodsman, A., Fraher, L., Adachi, J., A clinical trial of cyclical clodronate as maintenance therapy following withdrawal of parathyroid hormone in the treatment of postmenopausal osteoporosis (1995) J Bone Miner Res, 10 (SUPPL.), p. 200
Lindsay, R., Cosman, F., Shen, V., Bone mass increments induced by PTH treatment can be maintained by estrogen (1995) J Bone Miner Res, 10 (SUPPL.), p. 200
Cohen, F.E., Strewler, G.J., Bradley, S., Analogs of parathyroid hormone modified at positions 3 and 6 (1991) J Biol Chem, 266, pp. 1997-2004
Lane, N.E., Kimmel, D.B., Nilsson, M.H.L., Bone-selective analogs of human PTH (1-34) increase bone formation in ovariectomized rat model (1996) J Bone Miner Res, 1, pp. 614-625
Reifenstein, E.C., Albright, F., The metabolic effects of steroid hormones in osteoporosis (1947) J Clin Invest, 26, pp. 24-56
Kopera, H., The history of anabolic steroids and a review of clinical experience with anabolic steroids (1985) Acta Endocrinol, 10, pp. 11-18
Taggart, H.A., Applebaum-Bowden, D., Haffner, S., Reduction in high density lipoproteins by anabolic steroid (stanazolol) therapy for postmenopausal osteoporosis (1982) Metabolism, 3, pp. 1147-1152
Ishak, K.G., Zimmerman, H.J., Hepatotoxic effects or the anabolic/ androgenic steroids (1987) Semin Liver Dis, 7, pp. 230-236
Wilson, J., Griffin, J.E., The use and misuse of androgens (1980) Metabolism, 29, pp. 1278-1295
Geusens, P., Nandrolone decanoate: Pharmacological properties and therapeutic use in osteoporosis (1995) Clin Rheum, 14, pp. 32-39
Kasperck, C.H., Wergedal, J.E., Farley, J.R., Androgens directly stimulate proliferation of bone cells in vitro (1989) Endocrinology, 124, pp. 1576-1578
Riggs, B.L., Formation-stimulating regimens other than sodium fluoride (1993) Am J Med, 95, pp. 62-68
Geusens, P., Dequeker, J., Long-term effect of nandrolone decanoate, 1-α hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: A double-blind controlled study (1986) Bone Miner, 1, pp. 347-357
Hassager, C., Podenphant, J., Riis, B.J., Changes in soft tissue body composition and plasma lipid metabolism during nandrolone decanoate therapy in postmenopausal osteoporotic women (1989) Metabolism, 38, pp. 238-242
Need, A.G., Horowitz, M., Morris, H.A., Effects of nandrolone therapy on forearm bone mineral content in osteoporosis (1987) Clin Orthop, 225, pp. 273-278
Geusens, P., Dequeker, J., Verstraeten, Bone mineral content, cortical thickness and fracture rate in osteoporotic women after withdrawal of treatment with nandrolone decanoate, 1-α-hydroxyvitamin D3, or intermittent calcium infusions (1986) Maturitas, 8, pp. 281-289
Kanis, J.A., Johnell, O., Gullberg, B., Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture (1992) Bone Miner J, 305, pp. 1124-1128
Shore, R.M., Chesney, R.W., Mazess, R.B., Bone mineral status in growth hormone deficiency (1980) J Pediatr, 96, pp. 393-396
Marie, P.J., Garbat, M.T., Hott, M., Effect of low doses of stable strontium on bone metabolism in rats (1985) Miner Electrolyte Metab, 11, pp. 5-13
Marie, P.J., Hott, M., Short-term effects of fluoride and strontium on bone formation and resorption in the mouse (1986) Metabolism, 35, pp. 547-551
Grynpas, M.D., Hamilton, E., Cheung, R., Strontium increases vertebral bone volume in rats at a low dose that does not induce detectable mineralization defect (1996) Bone, 18, pp. 253-259
Boivin, G., Deloffre, P., Perrat, B., Strontium (Sr) distribution and interreactions with bone mineral in male monkey iliac bone after strontium salt (S-12911) administration (1996) Osteoporos Int, 6, p. 251
Amman, P., Rizzoli, R., Deloffre, P., The increase in vertebral bone mass induced in intact rats by long-term administration of the strontium salt S-12911 is directly correlated with vertebral bone strength (1996) Osteoporos Int, 6, p. 259
Meunier, P.J., Slosman, D., Delmas, P.D., The strontium salt S-12911: A new candidate for the treatment of osteoporosis (1996) Osteoporos Int, 6, p. 241
Kaufman, J.M., Taelman, P., Vermeulen, A., Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset (1993) J Clin Endocrinol Metab, 74, pp. 118-123
Demuinck Keizer-Schrama, S., Rikken, B., Wynne, H.J., Dose-response study of biosynthetic hGH in GH deficient children (1992) J Clin Endocrinol Metab, 74, pp. 898-905
Rudman, D., Feller, A.G., Nagraj, H.S., Effects of human growth hormone in men over 60 years old (1990) N Engl J Med, 323, pp. 1-6
Brixen, K., Nielsen, H.K., Mosekilde, L., A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers (1990) J Bone Miner Res, 5, pp. 609-618
Kelijman, M., Age-related alterations of the GH/IGF-I axis (1991) J Am Geriatr Soc, 39, pp. 295-307
Johansson, A.G., Lindh, E., Ljunghall, S., Insulin-like growth factor stimulates bone turnover in osteoporosis (1992) Lancet, 339, p. 1619
Aloia, J.F., Zanz, I., Ellis, K., Effects of GH in osteoporosis (1976) J Clin Endocrinol Metab, 43, pp. 992-999
Aloia, J.F., Vaswani, A., Meunier, P.J., Coherence treatment of postmenopausal osteoporosis with GH and calcitonin (1987) Calcif Tissue Int, 40, pp. 253-259
Johannson, A.G., Lindh, E., Blum, W.F., Effects of short-term treatment with IGF-1 and GH on markers of bone metabolism in idiopathic osteoporosis (1994) J Bone Miner Res, 9, p. 328
Ebeling, P.R., Jones, J.D., O'Fallon, W.M., Short term effects of recombinant human insulin-like growth factor I on bone turnover in normal women (1993) J Clin Endocrinol Metab, 77, pp. 1384-1387
Mohan, S., Bautista, C.M., Wergedal, J., Isolation of an inhibitory insulin-like growth factor (IGF) binding protein from bone cell-conditioned medium: A potential local regulator of IGF action (1989) Proc Natl Acad Sci USA, 86, pp. 8338-8342
Nasurawa, K., Nakaruma, T., Suzuki, K., The effects of recombinant human insulin-like growth factor (rhIFG)-1 and rhIFG-1/IGF binding protein-3 administration on rat osteopenia induced by ovariectomy with concomitant bilateral sciatic neurectomy (1995) J Bone Miner Res, 10, pp. 1853-1864
Cohen, P., Fluoride and calcium therapy by myeloma bone lesions (1966) JAMA, 198, pp. 583-586
Bellows, C.G., Heersche, J.N.M., Aubin, J.E., The effects of fluoride on osteoblast progenitors in vitro (1990) J Bone Miner Res, 5, pp. 101-105
Farley, J.R., Tarbaux, N., Hall, S., Mitogenic action(s) of fluoride on osteoblastline cells, determinants of the response in vitro (1990) J Bone Miner Res, 5, pp. 107-113
Kanis, J., Treatment of symptomatic osteoporosis with fluoride (1993) Am J Med, 95, pp. 53-61
Riggs, B.L., Hodgson, S.F., O'Fallon, W.M., Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis (1990) N Engl J Med, 322, pp. 802-809
Kleerekoper, M., Peterson, E.L., Nelson, D.A., A randomized trial of sodium fluoride as treatment for postmenopausal osteoporosis (1991) Osteoporos Int, 1, pp. 155-161
Reginster, J.Y., Meurmans, L., Zegels, B., The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis (1998) Ann Intern Med, 129, pp. 1-8
Mamelle, N., Meunier, P.J., Dusan, R., Risk-benefit ratio in sodium fluoride treatment in primary vertebral osteoporosis (1988) Lancet, 2, pp. 361-365
Pak, C.Y., Sakhaee, K., Adams-Huet, B., Treatment of postmenopausal osteoporosis with slow-release sodium fluoride: Final report of a randomized controlled trial (1995) Ann Intern Med, 123, pp. 401-408
Meunier, P.J., Sebert, J.L., Reginster, J.Y., Briancon, D., Appelboom, P., Netter, G., Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: The FAVOS study (1998) Osteoporos Int, 8, pp. 4-12
Saltman, P.D., Strause, L.G., The role of trace minerals in osteoporosis (1993) J Am Coll Nutr, 12, pp. 384-389
Reginster, J.Y., Roux, C., Riis, B.J., Design for IMEFS (ipriflavone multicentre European fracture study) (1996) Osteoporos Int, 6 (SUPPL. 1), p. 318
Biquet, I., Collette, J., Dauphin, J.F., Prevention of postmenopausal bone loss by administration of boron (1996) Osteoporos Int, 6, p. 249
Keeting, P.E., Oursler, M.J., Wiegand, K.E., Zeolite A increases proliferation, differentiation, and transforming growth factor beta production in normal adult human osteoblast-like cells in vitro (1992) J Bone Miner Res, 7, pp. 1281-1289
Franchimont, N., Franchimont, P., Gaspar, S., Organic silicon decreases interleukin 6 but not leukemia inhibiting factor production in human osteoblast like cells in vitro (1995) Bone, 16, p. 226
